Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
Pelican AI: +34,75% in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
29.10.Ascletis' challenger to Lilly's Foundayo hits goals in phase 2 diabetes trial
28.10.Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
28.10.FDA's rare disease framework aims to 'stand the test of time'
28.10.'The patient need is enormous': Syntax programs stem cells into pancreatic beta cells in 4 days
28.10.Biogen CEO tells analysts he's focused on early-stage R&D as 'we were not very good with that'
28.10.Lilly's retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
28.10.As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out the gate
28.10.GSK predicts 'some limited impact' to UK roles as restructuring rolls on
28.10.Astellas makes $1.3B bet on Audax's preclinical push to reverse decades of IL-12 woes
28.10.The 2026 Biotech Graveyard
27.10.From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
27.10.Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
27.10.Parkinson's-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
27.10.Corxel claims oral obesity drug is in the 'right lane' as biotech plans SPAC route to Nasdaq
27.10.Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
27.10.GSK's B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
27.10.BMS joins 3-year partnership to boost participation in cancer trials
26.10.Boehringer, Microsoft team up to explore digital patient twins for clinical trials
26.10.Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing
26.10.Windward Bio
26.10.ESMO: Why Incyte sees itself 'neck and neck' with RevMed in KRAS G12D pancreatic cancer race
26.10.Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing
26.10.ESMO: Genmab posts phase 3 win for Elahere rival, ahead of 'very interesting' data from Merus buyout
26.10.BioNTech sees 'limited' benefit to ADC after phase 3 reveals modest efficacy, ILD cases
26.10.BMS sheds light on patient death in CAR-T trial, wants to get program back on track